小鼠体内用Ly6G抗体,体内Gr-1+骨髓细胞去除

小鼠体内用Ly6G抗体,体内Gr-1+骨髓细胞去除

收藏
  • ¥5600
  • bioXCELL
  • 美国
  • BE0075-5mg
  • 2025年10月17日
    avatar
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 询价记录
    • 技术资料
    • 克隆性

      多克隆

    • 抗体英文名

      InVivoMAb anti-mouse Ly6G

    • 抗体名

      小鼠体内用Ly6G抗体,体内Gr-1+骨髓细胞去除

    • 规格

      5mg

    小鼠体内用Ly6G抗体,体内Gr-1+骨髓细胞去除
    InVivoMAb anti-mouse Ly6G
    Bio X Cell抗体优势:
    ✔ 通过大规模的组织培养生产抗体,亲和层析法纯化抗体,
    ✔ 所有抗体均具有高纯度(>95%)、低内毒素(<2EU/mg),无防腐剂和稳定剂的特性,适用于体内临床前研究
    ✔ 所有抗体可提供100mg甚至50g的大包装,性价比非常高
    Bio X Cell抗体应用
    小鼠体内用Ly6G抗体,体内Gr-1+骨髓细胞去除
    热销抗体
    抗原 应用 克隆号 InVivoMab
    目录号
    InVivoPlus
    目录号
    PD-1 体内PD-1/PD-L1信号封闭 RMP1-14 BE0146 BP0146
    体内PD-1/PD-L1信号封闭,体外PD-1中和,IHC(冰冻),IF,WB,FC 29F.1A12 BE0273 BP0273
    体内PD-1/PD-L1信号封闭,体外PD-1中和,WB J43 BE0033-2 BP0033-2
    InVivo rat IgG2a isotype control, PD-1同型对照,排除Fc段与抗原的非特异性结合 2A3 BE0089 BP0089
    PD-L1(B7-H1) 体内PD-L1信号封闭,IF,IHC(冰冻),FC,WB 10F.9G2 BE0101 BP0101
    InVivo rat IgG2b isotype control, PD-L1同型对照,排除Fc段与抗原的非特异性结合 LTF-2 BE0090 BP0090
    CTLA-4 体内 CTLA-4 中和,WB 9D9 BE0164 BP0164
    体内和体外中和CTLA-4,WB 9H10 BE0131 BP0131
    体内和体外中和CTLA-4,FC,WB UC10-
    4F10-11
    BE0032 BP0032
    NK1.1 体内NK细胞去除,FC PK136 BE0036 BP0036
    CD3ε 体内T细胞去除,体外T细胞刺激/激活,IF,FC,WB, 145-2C11 BE0001-1 BP0001-1
    CD4 体内CD4+T细胞去除,FC,WB GK1.5 BE0003-1 BP0003-1
    CD8α 体内CD8+T细胞去除,IF,FC,WB 53-6.7 BE0004-1 BP0004-1
    CD25 (IL-2Rα) 体内调节T细胞去除,FC PC-61.5.3 BE0012 BP0012
    CD28 体内CD8封闭,体外T细胞刺激/激活 37.51 BE0015-1 /
    体外T细胞刺激/激活 PV-1 BE0015-5 /
    CSF1R (CD115) 体内巨噬细胞去除,体外CSF-R1中和,体内单核细胞去除, FC,WB AFS98 BE0213 BP0213
    IL-4 体内IL-4中和,体外IL-4中和,体内IL-4受体刺激(as a complex with IL-4)
    FC,WB
    11B11 BE0045 BP0045
    IFNγ (interferon
    gamma)
    体内IFNγ中和,体外IFNγ中和,ELISPOT,FC,WB XMG1.2 BE0055 BP0055
    Ly6G 体内中性粒细胞耗竭,体内MDSC耗尽, IF,IHC(石蜡或冰冻),FC 1A8 BE0075-1 BP0075-1
    Ly6G/Ly6C (Gr-1) 体内Gr-1+骨髓细胞去除,IHC(石蜡或冰冻),FC RB6-8C5 BE0075 BP0075
    IFNAR-1 体内IFNAR-1阻断,体外IFNAR-1阻断,WB MAR1-5A3 BE0241 BP0241
    InVivoMab VS InVivoPlus
    - InVivoMab InVivoPlus
    纯度 >95% >95%
    蛋白完整性 √(SDS-PAGE) √(SDS-PAGE)
    内毒素浓度 2EU/mg <1EU/mg
    有效性验证(WB/FC/ELISA)
    蛋白聚集物<5%
    小鼠病原体测试
    无叠氮化物和载体蛋白
    大批量生产
    适用体内研究
    目录号 BE开头 BP开头
    InVivoPlusTM 系列抗体非常适用于高灵敏性实验以及用活细胞或整个动物进行各种功能测定的体内研究,可加快您的研究进展。

    热销同型对照和InVivoPure抗体稀释Buffer
    产品类型 品名 用途 InVivoMab
    目录号
    InVivoPlus
    目录号
    部分热卖同型
    对照
    InVivoMab rat IgG2a isotype control 排除一抗的Fc段与
    抗原的非特异性结合,
    使实验结果更加严谨,
    有助于您发表高分论文
    BE0089 BP0089
    InVivoMab rat IgG2b isotype control BE0090 BP0090
    InVivoMab mouse IgG1 isotype control BE0083 BP0083
    InVivoMAb human IgG1 isotype control BE0297 BP0297
    InVivoPlus rat IgG2a isotype control BE0089 BP0089
    InVivoMab mouse IgG2a isotype control BE0085 BP0085
    InVivoMabrat IgG1 isotype control BE0088 BP0088
    InVivoPlus mouse IgG1 isotype control BE0083 BP0083
    InVivoMAb polyclonal Armenian hamster IgG BE0091 BP0091
    抗体稀释Buffer InVivoPure pH 7.0 Dilution Buffer 官方指定抗体稀释
    buffer,确保抗体使用
    性能,加快您的实验进展
    IP0070 /
    InVivoPure pH 6.5 Dilution Buffer IP0065 /
    ✔ 为了加快您实验进度,确保实验结果的准确性,建议您搭配使用Bio X Cell一抗对应的同型对照(排除一抗的非特异性结合)和InVivoPure抗体稀释缓冲液。

    About InVivoMAb anti-mouse Ly6G

    The 1A8 monoclonal antibody reacts with mouse Ly6G. Ly6G is a 21-25 kDa member of the Ly-6 superfamily of GPI-anchored cell surface proteins with roles in cell signaling and cell adhesion. Ly6G is expressed differentially during development by cells in the myeloid lineage including monocytes, macrophages, granulocytes, and neutrophils. Monocytes typically express Ly6G transiently during development while mature granulocytes and peripheral neutrophils retain expression making Ly6G a good cell surface marker for these populations. Unlike the RB6-8C5 antibody, the 1A8 antibody reacts specifically with mouse Ly6G with no reported cross reactivity with Ly6C.

    InVivoMAb anti-mouse Ly6G Specifications

    Isotype Rat IgG2a, κ
    Recommended Isotype Control(s) InVivoMAb rat IgG2a isotype control, anti-trinitrophenol(BE0089)
    Recommended InVivoPure Dilution Buffer InVivoPure pH 7.0 Dilution Buffer(IP0070)
    Immunogen EL4J cells transfected with Ly6G
    Reported Applications
    • in vivo neutrophil depletion
    • in vivo MDSC depletion
    • Immunofluorescence
    • Immunohistochemistry (paraffin)
    • Immunohistochemistry (frozen)
    • Flow cytometry
    Endotoxin
    • <2EU/mg (<0.002EU/μg)
    • Determined by LAL gel clotting assay
    Purity
    • >95%
    • Determined by SDS-PAGE
    Formulation
    • PBS, pH 7.0
    • Contains no stabilizers or preservatives
    Sterility 0.2 μM filtered
    Production Purified from tissue culture supernatant in an animal free facility
    Purification Protein G
    Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
    RRID AB_1107721
    Molecular Weight 150 kDa

    Application References

    InVivoMAb anti-mouse Ly6G (Clone: 1A8)

    Davis, R. W. t., et al. (2018). "Luminol Chemiluminescence Reports Photodynamic Therapy-Generated Neutrophil Activity In Vivo and Serves as a Biomarker of Therapeutic Efficacy." Photochem Photobiol. PubMed Inflammatory cells, most especially neutrophils, can be a necessary component of the antitumor activity occurring after administration of photodynamic therapy. Generation of neutrophil responses has been suggested to be particularly important in instances when the delivered photodynamic therapy (PDT) dose is insufficient. In these cases, the release of neutrophil granules and engagement of antitumor immunity may play an important role in eliminating residual disease. Herein, we utilize in vivo imaging of luminol chemiluminescence to noninvasively monitor neutrophil activation after PDT administration. Studies were performed in the AB12 murine model of mesothelioma, treated with Photofrin-PDT. Luminol-generated chemiluminescence increased transiently 1 h after PDT, followed by a subsequent decrease at 4 h after PDT. The production of luminol signal was not associated with the influx of Ly6G(+) cells, but was related to oxidative burst, as an indicator of neutrophil function. Most importantly, greater levels of luminol chemiluminescence 1 h after PDT were prognostic of a complete response at 90 days after PDT. Taken together, this research supports an important role for early activity by Ly6G(+) cells in the generation of long-term PDT responses in mesothelioma, and it points to luminol chemiluminescence as a potentially useful approach for preclinical monitoring of neutrophil activation by PDT.

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    • 作者
    • 内容
    • 询问日期
    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥7280
    上海研卉生物科技有限公司
    2025年12月17日询价
    询价
    武汉佰瑞得生物技术有限公司
    2025年07月12日询价
    询价
    上海古朵生物科技有限公司
    2025年07月15日询价
    ¥2400
    深圳市豪地华拓生物科技有限公司
    2025年07月14日询价
    小鼠体内用Ly6G抗体,体内Gr-1+骨髓细胞去除
    ¥5600